Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 76.

Journal Article

Al-Sawaf, Othman, Bazeos, Alexandra, Robrecht, Sandra, Bahlo, Jasmin, Gower, Craig, Fink, Anna-Maria, Tresckow, Julia, Cramer, Paula, Langerbeins, Petra, Kutsch, Nadine, Humphrey, Kathryn, Fingerle-Rowson, Guenter, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Goede, Valentin (2019). Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL). Am. J. Hematol., 94 (9). S. 1002 - 1007. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Fischer, Kirsten, Herling, Carmen D., Ritgen, Matthias, Boettcher, Sebastian, Bahlo, Jasmin, Elter, Thomas, Stilgenbauer, Stephan, Eichhorst, Barbara F., Busch, Raymonde, Elberskirch, Ute, Abenhardt, Wolfgang, Kneba, Michael, Hallek, Michael and Wendtner, Clemens-Martin (2017). Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur. J. Haematol., 98 (3). S. 254 - 263. HOBOKEN: WILEY. ISSN 1600-0609

Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Gentile, Brittany ORCID: 0000-0002-6302-5593, Devine, Jacob, Zhang, Can, Sail, Kavita, Tandon, Maneesh, Fink, Anna-Maria, Kutsch, Nadine, Wendtner, Clemens-Martin, Eichhorst, Barbara, Hallek, Michael and Fischer, Kirsten (2021). Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. Am. J. Hematol., 96 (9). S. 1112 - 1120. HOBOKEN: WILEY. ISSN 1096-8652

Al-Sawaf, Othman, Robrecht, Sandra, Bahlo, Jasmin, Fink, Anna Maria, Cramer, Paula, Maurer, Christian, Bergmann, Manuela A., Dreyling, Martin H., Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Dohner, Hartmut, Kiehl, Michael G., Jager, Ulrich, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara F. and Hopfinger, Georg (2016). Impact of Gender on Outcome after Chemoimmunotherapy with Fludarabine, Cyclophosphamide and Rituximab (FCR) or Bendamustine Plus Rituximab (BR) in Patients with Chronic Lymphocytic Leukemia (CLL): A Meta-Analysis of Three Phase II/III Studies of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Al-Sawaf, Othman, Zhang, Can, Lu, Tong, Liao, Michael Z., Panchal, Anesh, Robrecht, Sandra, Ching, Travers ORCID: 0000-0002-5577-3516, Tandon, Maneesh, Fink, Anna-Maria, Tausch, Eugen, Schneider, Christof, Ritgen, Matthias, Boettcher, Sebastian, Kreuzer, Karl-Anton, Chyla, Brenda, Miles, Dale, Wendtner, Clemens-Martin, Eichhorst, Barbara, Stilgenbauer, Stephan, Jiang, Yanwen, Hallek, Michael and Fischer, Kirsten (2021). Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. J. Clin. Oncol., 39 (36). S. 4049 - 4062. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755

Al-Sawaf, Othman, Zhang, Can, Tandon, Maneesh, Sinha, Arijit, Fink, Anna-Maria, Robrecht, Sandra, Samoylova, Olga, Liberati, Anna M., Pinilla-Ibarz, Javier, Opat, Stephen, Sivcheva, Liliya, Le Du, Katell, Fogliatto, Laura M., Niemann, Carsten U., Weinkove, Robert, Robinson, Sue, Kipps, Thomas J., Tausch, Eugen, Schary, William, Ritgen, Matthias, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Eichhorst, Barbara, Stilgenbauer, Stephan, Hallek, Michael and Fischer, Kirsten (2020). Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol., 21 (9). S. 1188 - 1201. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Bahlo, Jasmin, Pflug, Natali, Elter, Thomas, Bauer, Kathrin, Eichhorst, Barbara, Bergmann, Manuela, Busch, Raymonde, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Fischer, Kirsten and Hallek, Michael (2011). Proposal of A Prognostic Score for Previously Untreated Patients with Chronic Lymphocytic Leukemia Based on An Overall Survival Analysis of Three German CLL Study Group Phase III Trials. Blood, 118 (21). S. 1219 - 1221. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Beckmann, Laura, Berg, Valeska, Dickhut, Clarissa, Bloehdorn, Johannes, Bahlo, Jasmin, Robrecht, Sandra, Huelsemann, Malte, Loroch, Stefan, Merkel, Olaf, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Sickmann, Albert ORCID: 0000-0002-2388-5265, Hallek, Michael, Zahedi, Rene and Frenzel, Lukas P. (2018). Integrated Proteomic and Phosphoproteomic Analysis Reveal Novel Targets and Suggest Rationale for Ibrutinib Efficacy in UM-CLL. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Berg, Valeska, Rusch, Marion, Vartak, Nachiket, Juengst, Christian, Schauss, Astrid, Waldmann, Herbert ORCID: 0000-0002-9606-7247, Hedberg, Christian, Pallasch, Christian P., Bastiaens, Philippe, Hallek, Michael, Wendtner, Clemens-Martin and Frenzel, Lukas P. (2014). Mirs-138 and-424 Control Palmitoylation-Dependent CD95-Mediated Cell Death By Targeting Acyl Protein Thioesterases 1 and 2 in Chronic Lymphocytic Leukemia. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, Fink, Anna-Maria, Busch, Raymonde, Eichhorst, Barbara, Wendtner, Clemens-Martin, Pflug, Natali, Schubert, Friederike, Doehner, Hartmut, Rieger, Michael, Kneba, Michael, Mayer, Jiri, Hallek, Michael and Fischer, Kirsten (2011). Second-Line Therapies After Treatment with Fludarabine, Cyclophosphamide, and Rituximab (FCR) or Fludarabine and Cyclophosphamid Alone (FC) for Chronic Lymphocytic Leukemia (CLL) within the CLL8-Protocol of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 1235 - 1236. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Cramer, Paula, Isfort, Susanne, Bahlo, Jasmin, Stilgenbauer, Stephan, Doehner, Hartmut, Bergmann, Manuela, Stauch, Martina, Kneba, Michael, Lange, Elisabeth, Langerbeins, Petra, Pflug, Natali, Kovacs, Gabor, Goede, Valentin, Fink, Anna-Maria, Elter, Thomas, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2015). Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica, 100 (11). S. 1451 - 1460. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria ORCID: 0000-0002-7669-7890, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2021). Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations. Blood, 138 (19). S. 1805 - 1817. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2018). CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia. Future Oncol., 14 (6). S. 499 - 514. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Wesselmann, Johanna Sofie, Annolleck, Tanja, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG, -BAG, -BCG and -BIO: a series of four phase-II trials evaluating a sequential tailored and targeted regimen aiming for total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia. Leuk. Lymphoma, 56. S. 143 - 145. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Balke-Want, Hyatt, Al-Sawaf, Othman, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Fischer, Kirsten, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara F. and Hallek, Michael (2016). Low Incidence of Tumor Lysis Syndromes (TLS) and Infusion Related Reactions (IRR) in the CLL2-Bag Trial Evaluating a Sequential Treatment of Bendamustine (B), Obinutuzumab (GA101, G) and Venetoclax (ABT-199, A) in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Safety Results of a Phase-II-Trial of the German CLL Study Group (GCLLSG). Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Al-Sawaf, Othman, Engelke, Anja, Fink, Anna-Maria, Fischer, Kirsten, Tausch, Eugen, Seiler, Till, von Weikersthal, Ludwig Fischer, Hebart, Holger, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2018). Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol., 19 (9). S. 1215 - 1229. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Cramer, Paula, von Tresckow, Julia, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Fuerstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2018). Durable Remissions after Discontinuation of Combined Targeted Treatment in Patients with Chronic Lymphocytic Leukemia (CLL) Harbouring a High-Risk Genetic Lesion (del(17p)/TP53 Mutation). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz ORCID: 0000-0002-6593-0140, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman ORCID: 0000-0001-9895-0570, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO). Haematologica, 106 (2). S. 543 - 555. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Dietrich, Sascha, Pircher, Andreas ORCID: 0000-0002-7747-3012, Endris, Volker, Peyrade, Frederic, Wendtner, Clemens-Martin, Follows, George A., Huellein, Jennifer, Jethwa, Alexander ORCID: 0000-0003-3869-8662, Ellert, Elena, Walther, Tatjana, Liu, Xiyang, Dyer, Martin J. S., Elter, Thomas, Brummer, Tilman ORCID: 0000-0003-4387-7905, Zeiser, Robert, Hermann, Michael, Herold, Michael, Weichert, Wilko, Dearden, Claire, Haferlach, Torsten, Seiffert, Martina ORCID: 0000-0001-5155-663X, Hallek, Michael, von Kalle, Christof, Ho, Anthony D., Gaehler, Anita, Andrulis, Mindaugas, Steurer, Michael and Zenz, Thorsten (2016). BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood, 127 (23). S. 2847 - 2856. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichenauer, Dennis A. ORCID: 0000-0002-1927-3514, Buehnen, Ina, Pluetschow, Annette, Kobe, Carsten, Dietlein, Markus, Wendtner, Clemens-Martin, Thorspecken, Sven, Topp, Max S., Mauser, Mareike, von Tresckow, Bastian, Fuchs, Michael, Borchmann, Peter and Engert, Andreas (2022). Phase II study of fixed-duration single-agent ibrutinib in relapsed nodular lymphocyte-predominant Hodgkin lymphoma: A report from the German Hodgkin Study Group. Hematol. Oncol., 40 (4). S. 801 - 805. HOBOKEN: WILEY. ISSN 1099-1069

Eichhorst, Barbara, Bahlo, Jasmin, Fink, Anna Maria, Pfreundschuh, Michael, Hebart, Holger, Maschmeyer, Georg, Jentsch-Ulrich, Kathleen, Doerfel, Steffen, Westermann, Anne, Zey, Aline, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Kreuzer, Karl-Anton, Doehner, Hartmut, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Good Tolerance of Lenalidomide Maintenance Therapy in Patients with High Risk Profile Chronic Lymphocytic Leukemia (CLL) after Frontline Chemoimmunotherapy: Preliminary Safety Overview of the CLLM1 Trial of the German CLL Study Group (GCLLSG). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Fink, Anna Maria, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg R. A., Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2014). Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Eichhorst, Barbara, Fink, Anna-Maria, Bahlo, Jasmin, Busch, Raymonde, Kovacs, Gabor, Maurer, Christian, Lange, Elisabeth, Koeppler, Hubert, Kiehl, Michael, Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Trneny, Marek ORCID: 0000-0002-6952-6073, Fischer, Kirsten, Doehner, Harmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian and Hallek, Michael (2016). First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol., 17 (7). S. 928 - 943. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Faitschuk, Elena, Hombach, Andreas A., Frenzel, Lukas P., Wendtner, Clemens-Martin and Abken, Hinrich (2016). Chimeric antigen receptor T cells targeting Fc mu receptor selectively eliminate CLL cells while sparing healthy B cells. Blood, 128 (13). S. 1711 - 1723. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fink, Anna, Busch, Raymonde, Pflug, Natali, Boettcher, Sebastian, Winkler, Dirk, Buehler, Andreas, Ritgen, Matthias, Fischer, Kirsten, Eichhorst, Barbara, Wendtner, Clemens-Martin, Mendila, Myriam, Wenger, Michael K., Doehner, Hartmut, Kneba, Michael, Stilgenbauer, Stephan and Hallek, Michael (2011). Prediction of Poor Outcome in CLL Patients Treated with FCR (Fludarabine, Cyclophosphamide, Rituximab) in the CLL8 Trial of the German CLL Study Group (GCLLSG). Blood, 118 (21). S. 446 - 448. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fink, Anna Maria, Bahlo, Jasmin, Robrecht, Sandra, Al-Sawaf, Othman, Aldaoud, Ali, Hebart, Holger, Jentsch-Ullrich, Kathleen, Doerfel, Steffen, Fischer, Kirsten, Wendtner, Clemens-Martin, Noesslinger, Thomas, Ghia, Paolo ORCID: 0000-0003-3750-7342, Bosch, Francesc ORCID: 0000-0001-9241-2886, Kater, Arnon P., Dohner, Hartmut, Kneba, Michael, Kreuzer, Karl-Anton, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2017). Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol., 4 (10). S. E475 - 12. OXFORD: ELSEVIER SCI LTD. ISSN 2352-3026

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna Maria, Goede, Valentin, Herling, Carmen Diana, Cramer, Paula, Langerbeins, Petra, von Tresckow, Julia, Engelke, Anja, Maurer, Christian, Kovacs, Gabor, Herling, Marco, Tausch, Eugen, Kreuzer, Karl-Anton, Eichhorst, Barbara, Boettcher, Sebastian, Seymour, John F., Ghia, Paolo ORCID: 0000-0003-3750-7342, Marlton, Paula, Kneba, Michael, Wendtner, Clemens-Martin, Doehner, Hartmut, Stilgenbauer, Stephan and Hallek, Michael (2016). Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood, 127 (2). S. 208 - 216. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fischer, Kirsten, Bahlo, Jasmin, Fink, Anna-Maria, Busch, Raymonde, Boettcher, Sebastian, Mayer, Jiri, Dreger, Peter, Maurer, Christian, Engelke, Anja, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Wendtner, Clemens-Martin, Stilgenbauer, Stephan and Hallek, Michael (2012). Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen. Blood, 120 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Boettcher, Sebastian, Bahlo, Jasmin, Schubert, Joeerg, Pflueger, Karl H., Schott, Silke, Goede, Valentin, Isfort, Susanne, von Tresckow, Julia, Fink, Anna-Maria, Buehler, Andreas, Winkler, Dirk, Kreuzer, Karl-Anton, Staib, Peter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael, Stilgenbauer, Stephan and Wendtner, Clemens-Martin (2012). Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol., 30 (26). S. 3209 - 3217. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fischer, Kirsten, Cramer, Paula, Busch, Raymonde, Stilgenbauer, Stephan, Bahlo, Jasmin, Schweighofer, Carmen D., Boettcher, Sebastian, Staib, Peter, Kiehl, Michael, Eckart, Michael J., Kranz, Gabriele, Goede, Valentin, Elter, Thomas, Buehler, Andreas, Winkler, Dirk, Kneba, Michael, Doehner, Hartmut, Eichhorst, Barbara F., Hallek, Michael and Wendtner, Clemens-Martin (2011). Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol., 29 (26). S. 3559 - 3567. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Fischer, Kirsten, Fink, Anna-Maria, Bishop, Helen, Dixon, Mark, Bahlo, Jasmin, Chol, Michael Y., Weinkove, Robert ORCID: 0000-0003-3645-7988, Robinson, Sue, Dreyling, Martin, Seiler, Till, Opat, Stephen, Owen, Carolyn, Lopez, Javier, Sr., Kutsch, Nadine, Tausch, Eugen, Ritgen, Matthias, Humerickhouse, Rod A., Humphrey, Kathryn, Wenger, Michael K., Goede, Valentin, Eichhorst, Barbara, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Kipps, Thomas J. and Hallek, Michael (2015). Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase Ill Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Theurich, Sebastian (2018). Obesity Negatively Impacts Outcome in Female Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR): An Analysis of Three Phase III Studies of the German CLL Study Group (GCLLSG). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Fuerstenau, Moritz, Hopfinger, Georg, Robrecht, Sandra, Fink, Anna-Maria, Al-Sawaf, Othman, Langerbeins, Petra, Cramer, Paula, Von Tresckow, Julia, Maurer, Christian, Kutsch, Nadine, Hoechstetter, Manuela, Dreyling, Martin, Lange, Elisabeth, Kneba, Michael, Stilgenbauer, Stephan, Doehner, Hartmut, Hensel, Manfred, Kiehl, Michael G., Jaeger, Ulrich, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, von Bergwelt-Baildon, Michael, Eichhorst, Barbara, Hallek, Michael and Theurich, Sebastian ORCID: 0000-0001-5706-8258 (2020). Influence of obesity and gender on treatment outcomes in patients with chronic lymphocytic leukemia (CLL) undergoing rituximab-based chemoimmunotherapy. Leukemia, 34 (4). S. 1177 - 1182. LONDON: SPRINGERNATURE. ISSN 1476-5551

Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael and Eichhorst, Barbara (2018). Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M. N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjorn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C., Lindstroem, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brueggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton and Kater, Arnon P. (2022). High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Grossmann, Vera, Schnittger, Susanne, Kohlmann, Alexander, Eder, Christiane, Roller, Andreas, Dicker, Frank, Schmid, Christoph, Wendtner, Clemens-Martin, Staib, Peter, Serve, Hubert ORCID: 0000-0001-8472-5516, Kreuzer, Karl-Anton, Kern, Wolfgang, Haferlach, Torsten and Haferlach, Claudia (2012). A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood, 120 (15). S. 2963 - 2973. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Guerreiro, Alexandra da Palma, Dorweiler, Cornelia, Halmer, Ismini, Merkel, Olaf, Hartmann, Elena Maria, Berg, Valeska, Reinart, Nina, Fingerle-Rowson, Guenter, Knittel, Gero, Pallasch, Christian, Rosenwald, Andreas, Reinhardt, Christian, Wendtner, Clemens-Martin, Hallek, Michael and Frenzel, Lukas P. (2018). FcmR Shapes BCR Signaling in IgM-Positive Leukemia. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Herling, Carmen D., Abedpour, Nima, Weiss, Jonathan, Schmitt, Anna, Jachimowicz, Ron Daniel, Merkel, Olaf ORCID: 0000-0001-5089-344X, Cartolano, Maria, Oberbeck, Sebastian, Mayer, Petra, Berg, Valeska, Thomalla, Daniel, Kutsch, Nadine, Stiefelhagen, Marius, Cramer, Paula, Wendtner, Clemens-Martin ORCID: 0000-0003-2866-2260, Persigehl, Thorsten, Saleh, Andreas, Altmueller, Janine, Nuernberg, Peter, Pallasch, Christian, Achter, Viktor, Lang, Ulrich, Eichhorst, Barbara, Castiglione, Roberta ORCID: 0000-0002-9828-4405, Schaefer, Stephan C., Buettner, Reinhard, Kreuzer, Karl-Anton, Reinhardt, Hans Christian, Hallek, Michael, Frenzel, Lukas P. and Peifer, Martin ORCID: 0000-0002-5243-5503 (2018). Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723

Huelsemann, Malte F., Patz, Michaela, Beckmann, Laura, Brinkmann, Kerstin, Otto, Teresa, Fandrey, Joachim, Becker, Hans Jiro, Theurich, Sebastian, von Bergwelt-Baildon, Michael S., Pallasch, Christian P., Zahedi, Rene P., Kashkar, Hamid, Reinhardt, Christian, Hallek, Michael, Wendtner, Clemens-Martin and Frenzel, Lukas P. (2014). p38 MAPK Controls Sensitivity Towards BH3 Mimetics By Regulating Mcl-1 Expression of Chronic Lymphocytic Leukemia in Hypoxia and Acquired Resistance. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Jenke, Petra, Eichhorst, Barbara, Busch, Raymonde, Anheier, Nadine, Duehrsen, Ulrich, Duerig, Jan, Dreyling, Martin H., Bergmann, Manuela, Goebeler, Maria Elisabeth, Hurts, Hans Juergen, Stauch, Martina Beate, Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin and Hallek, Michael (2011). Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group. Blood, 118 (21). S. 1233 - 1235. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 0006-4971

Kovacs, Gabor, Bahlo, Jasmin, Kluth, Sandra, Cramer, Paula, Fink, Anna-Maria, Fischer, Kirsten, Gross-Ophoff-Mueller, Carolin, Langerbeins, Petra, Maurer, Christian, von Tresckow, Julia, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Hallek, Michael, Eichhorst, Barbara and Goede, Valentin (2015). Prognostic Impact and Risk Factors of Reducing Prescribed Doses of Fludarabine, Cyclophosphamide and Rituximab (FCR) during Frontline Treatment of Chronic Lymphocytic Leukemia (CLL). Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Kovacs, Gabor, Robrecht, Sandra, Fink, Anna Maria, Bahlo, Jasmin, Cramer, Paula, von Tresckow, Julia, Maurer, Christian, Langerbeins, Petra, Fingerle-Rowson, Gunter, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Klapper, Wolfram, Wendtner, Clemens-Martin, Fischer, Kirsten, Hallek, Michael, Eichhorst, Barbara and Boettcher, Sebastian (2016). Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group. J. Clin. Oncol., 34 (31). S. 3758 - 3775. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Kutsch, Nadine, Bahlo, Jasmin, Robrecht, Sandra, Franklin, Jeremy, Zhang, Can, Maurer, Christian, De Silva, Nisha, Lange, Elisabeth, Weide, Rudolf, Kiehl, Michael G., Soekler, Martin, Schlag, Rudolf, Vehling-Kaiser, Ursula, Koechling, Georg, Ploeger, Christoph, Gregor, Michael, Plesner, Torben, Herling, Marco, Fischer, Kirsten, Doehner, Hartmut, Kneba, Michael, Wendtner, Clemens-Martin, Klapper, Wolfram, Kreuzer, Karl-Anton, Boettcher, Sebastian, Stilgenbauer, Stephan, Fink, Anna Maria, Hallek, Michael and Eichhorst, Barbara (2020). Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG). Hemasphere, 4 (1). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Kutsch, Nadine, Busch, Raymonde, Bahlo, Jasmin, Mayer, Jiri, Hensel, Manfred, Hopfinger, Georg ORCID: 0000-0002-8321-1342, Hess, Georg, von Gruenhagen, Ulrich, Wendtner, Clemens-Martin, Fink, Anna Maria, Fischer, Kirsten, Hallek, Michael and Eichhorst, Barbara (2017). FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia. Leuk. Lymphoma, 58 (2). S. 399 - 408. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Holmes, Emily Eva, Robrecht, Sandra, Schueler, Gudrun, Vehling-Kaiser, Ursula, Decker, Thomas, Mueller-Hagen, Sigrun, Heinisch, Karin, Boettcher, Sebastian, Ritgen, Matthias, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Fink, Anna Maria, Fischer, Kirsten, Eichhorst, Barbara, Hallek, Michael and Wendtner, Clemens-Martin (2023). Efficacy and safety of obinutuzumab combined with fludarabine and cyclophosphamide (FCG) or bendamustine (BG) in relapsed or refractory CLL patients followed by maintenance therapy with obinutuzumab for responding patients. Leuk. Lymphoma, 64 (2). S. 478 - 483. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Kutsch, Nadine, Pallasch, Christian, Decker, Thomas ORCID: 0000-0003-3814-8775, Hebart, Holger, Chow, Kai Uwe, Graeven, Ullrich, Kisro, Jens, Kroeber, Alexander, Tausch, Eugen, Fischer, Kirsten, Fink, Anna-Maria, Wendtner, Clemens-Martin, Ritgen, Matthias, Stilgenbauer, Stephan, Zhang, Danjie, Li, Biao, Jurgensmeier, Juliane M., Rajakumaraswamy, Nishanthan, Bhargava, Pankaj, Hallek, Michael ORCID: 0000-0002-7425-4455 and Eichhorst, Barbara (2022). Efficacy and Safety of Tirabrutinib and Idelalisib With or Without Obinutuzumab in Relapsed Chronic Lymphocytic Leukemia. Hemasphere, 6 (6). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 2572-9241

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna Maria, Pflug, Natali, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Preliminary safety results of a placebo-controlled Phase III study of ibrutinib in treatment-nayve early stage CLL patients with risk of disease progression. Leuk. Lymphoma, 56. S. 20 - 22. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Fink, Anna-Maria, Pflug, Natali, von Tresckow, Julia, Stilgenbauer, Stephan, Kreuzer, Karl-Anton, Eckart, Michael J., Vehling-Kaiser, Ursula, Schlag, Rudolf, Balser, Christina, Mueller, Lothar, Wendtner, Clemens-Martin, Fischer, Kirsten, Eichhorst, Barbara and Hallek, Michael (2015). Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Langerbeins, Petra, Bahlo, Jasmin, Rhein, Christina, Cramer, Paula, Pflug, Natali, Fischer, Kirsten, Stilgenbauer, Stephan, Kreuzer, Karl Anton, Wendtner, Clemens-Martin, Eichhorst, Barbara and Hallek, Michael (2015). The CLL12 trial protocol: a placebo-controlled double-blind Phase III study of ibrutinib in the treatment of early-stage chronic lymphocytic leukemia patients with risk of early disease progression. Future Oncol., 11 (13). S. 1895 - 1904. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Langerbeins, Petra, Busch, Raymonde, Anheier, Nadine, Duerig, Jan, Bergmann, Manuela, Goebeler, Maria-Elisabeth, Hurtz, Hans-Juergen, Stauch, Martina B., Stilgenbauer, Stephan, Doehner, Hartmut, Fink, Anna-Maria, Cramer, Paula, Fischer, Kirsten, Wendtner, Clemens-Martin, Hallek, Michael and Eichhorst, Barbara (2014). Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am. J. Hematol., 89 (12). S. E239 - 5. HOBOKEN: WILEY. ISSN 1096-8652

Langerbeins, Petra, Zhang, Can, Robrecht, Sandra, Cramer, Paula, Fuerstenau, Moritz, Al-Sawaf, Othman, von Tresckow, Julia, Fink, Anna-Maria, Kreuzer, Karl-Anton, Vehling-Kaiser, Ursula, Tausch, Eugen, Mueller, Lothar, Eckart, Michael Josef, Schlag, Rudolf, Freier, Werner, Gaska, Tobias, Balser, Christina, Reiser, Marcel, Stauch, Martina, Wendtner, Clemens-Martin, Fischer, Kirsten, Stilgenbauer, Stephan, Eichhorst, Barbara and Hallek, Michael (2021). The CLL12 trial: ibrutinib vs placebo in treatment-naive, early-stage chronic lymphocytic leukemia. Blood, 139 (2). S. 177 - 188. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Maurer, Christian, Pflug, Natali, Bahlo, Jasmin, Kluth, Sandra, Rhein, Christina, Cramer, Paula, Gross-Ophoff, Carolin, Langerbeins, Petra, Fink, Anna-Maria, Eichhorst, Barbara, Kreuzer, Karl-Anton, Fischer, Norbert, Tausch, Eugen, Stilgenbauer, Stephan, Boettcher, Sebastian, Doehner, Hartmut, Kneba, Michael, Dreyling, Martin, Binder, Mascha ORCID: 0000-0003-0663-3004, Hallek, Michael, Wendtner, Clemens-Martin, Bergmann, Manuela and Fischer, Kirsten (2016). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. Eur. J. Haematol., 97 (3). S. 253 - 261. HOBOKEN: WILEY. ISSN 1600-0609

Pflug, Natali, Bahlo, Jasmin, Shanafelt, Tait D., Eichhorst, Barbara F., Bergmann, Manuela A., Elter, Thomas, Bauer, Kathrin, Malchau, Gebhart, Rabe, Kari G., Stilgenbauer, Stephan, Doehner, Hartmut, Jaeger, Ulrich, Eckart, Michael J., Hopfinger, Georg, Busch, Raymonde, Fink, Anna-Maria, Wendtner, Clemens-Martin, Fischer, Kirsten, Kay, Neil E. and Hallek, Michael (2014). Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood, 124 (1). S. 49 - 63. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Salles, Gilles A., Boyd, Thomas E., Morschhauser, Franck, Wendtner, Clemens-Martin, Hallek, Michael, Eichhorst, Barbara F., Kozloff, Mark, Cartron, Guillaume, Li, Yan, Hilger, James, Mobasher, Mehrdad and Stilgenbauer, Stephan (2015). Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Sascha, Dietrich, Pircher, Andreas ORCID: 0000-0002-7747-3012, Andrulis, Mindaugas, Ellert, Elena, Peyrade, Frederic, Wendtner, Clemens-Martin, Follows, George A., Dyer, Martin J. S., Elter, Thomas, Zeiser, Robert, Gaehler, Anita, Herrmann, Michael, Herold, Michael, Dearden, Claire, Glimm, Hanno, Hallek, Michael, Ho, Anthony D., Steurer, Michael and Zenz, Thorsten (2014). BRAF Inhibition in Hairy Cell Leukemia: Multicentre Experience of 21 Patients Treated with Vemurafenib. Blood, 124 (21). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Schwamb, Janine, Feldhaus, Valeska, Baumann, Michael, Patz, Michaela, Brodesser, Susanne, Brinker, Reinhild, Claasen, Julia, Pallasch, Christian P. ORCID: 0000-0001-5675-6905, Hallek, Michael, Wendtner, Clemens-Martin and Frenzel, Lukas P. (2012). B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood, 120 (19). S. 3978 - 3986. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Simon, Florian, Giza, Adam, Robrecht, Sandra, Fink, Anna-Maria, Cramer, Paula ORCID: 0000-0003-4046-9922, von Tresckow, Julia, Fuerstenau, Moritz, Goede, Valentin, Tausch, Eugen, Schneider, Christof, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Eichhorst, Barbara, Fischer, Kirsten, Hallek, Michael ORCID: 0000-0002-7425-4455 and Al-Sawaf, Othman (2022). Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Leuk. Lymphoma, 63 (14). S. 3299 - 3307. ABINGDON: TAYLOR & FRANCIS LTD. ISSN 1029-2403

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Desai, Monali, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod, Gordon, Gary, Hallek, Michael and Wierda, William G. (2016). Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol., 17 (6). S. 768 - 779. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488

Stilgenbauer, Stephan, Eichhorst, Barbara, Schetelig, Johannes, Hillmen, Peter, Seymour, John F., Coutre, Steven, Jurczak, Wojciech ORCID: 0000-0003-1879-8084, Mulligan, Stephen P., Schuh, Anna, Assouline, Sarit, Wendtner, Clemens-Martin, Roberts, Andrew W., Davids, Matthew S., Bloehdorn, Johannes, Munir, Talha, Boettcher, Sebastian, Zhou, Lang, Salem, Ahmed Hamed, Desai, Monali, Chyla, Brenda, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Gordon, Gary, Hallek, Michael and Wierda, William G. (2018). Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J. Clin. Oncol., 36 (19). S. 1973 - 1984. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Stilgenbauer, Stephan, Eichhorst, Barbara F., Schetelig, Johannes, Coutre, Steven, Seymour, John F., Munir, Talha, Puvvada, Soham D., Wendtner, Clemens-Martin, Roberts, Andrew W., Jurczak, Wojciech, Mulligan, Stephen, Boettcher, Sebastian, Mobasher, Mehrdad, Zhu, Ming, Chyla, Brenda, Verdugo, Maria, Enschede, Sari Heitner, Cerri, Elisa, Humerickhouse, Rod A., Gordon, Gary, Hallek, Michael and Wierda, William (2015). Venetoclax (ABT-199/GDC-0199) Monotherapy Induces Deep Remissions, Including Complete Remission and Undetectable MRD, in Ultra-High Risk Relapsed/Refractory Chronic Lymphocytic Leukemia with 17p Deletion: Results of the Pivotal International Phase 2 Study. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara, Kozloff, Mark F., Giever, Thomas, Lozanski, Gerard, Jiang, Yanwen, Huang, Huang, Pignataro, Daniela Soriano, Schary, William, Humphrey, Kathryn, Mobasher, Mehrdad and Salles, Gilles (2018). Safety and Efficacy of Venetoclax (VEN) in Combination with Bendamustine (B) Plus Rituximab (R) or Obinutuzumab (G) in Patients (pts) with Previously Untreated Chronic Lymphocytic Leukemia (CLL): Results from a Phase Ib Study (GO28440). Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara, Kozloff, Mark F., Giever, Thomas, Lozanski, Gerard, Jiang, Yanwen, Huang, Huang, Pignataro, Daniela Soriano, Schary, William, Humphrey, Kathryn, Mobasher, Mehrdad and Salles, Gilles (2021). Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440). Haematologica, 106 (11). S. 2834 - 2845. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Stilgenbauer, Stephan, Morschhauser, Franck, Wendtner, Clemens-Martin, Cartron, Guillaume, Hallek, Michael, Eichhorst, Barbara F., Kozloff, Mark, Giever, Thomas A., Lozanski, Gerard, Punnoose, Elizabeth A., Wang, Jue, Hilger, James, Mobasher, Mehrdad and Salles, Gilles (2016). Phase Ib Study (GO28440) of Venetoclax with Bendamustine/Rituximab or Bendamustine/Obinutuzumab in Patients with Relapsed/ Refractory or Previously Untreated Chronic Lymphocytic Leukemia. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara and Stilgenbauer, Stephan (2022). Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Vorholt, Daniela, Izquierdo-Alvarez, Elena, Sackey, Benedict, Schmitz, Jan, Nickel, Nadine, Blakemore, Stuart, Knittel, Gero, Reinhardt, Christian, Wendtner, Clemens-Martin, Bruns, Heiko, Hallek, Michael and Pallasch, Christian (2018). DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-Li Expression and Fxosome Formation. Blood, 132. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Voth, Harald, Nakai, Noriaki, Wardelmann, Eva, Wenzel, Joerg, Bieber, Thomas, Wendtner, Clemens-Martin, Reinhard, Guenter and Schmid-Wendtner, Monika-Hildegard (2011). Malignant Peripheral Nerve Sheath Tumor of the Scalp: Case Report and Review of the Literature. Dermatol. Surg., 37 (11). S. 1684 - 1689. HOBOKEN: WILEY-BLACKWELL. ISSN 1524-4725

Wendtner, Clemens-Martin (2018). Bendamustine plus rituximab in chronic lymphocytic leukemia: is there life in the old dog yet? Haematologica, 103 (4). S. 563 - 565. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078

Wendtner, Clemens-Martin (2019). Ibrutinib: the home run for cure in CLL? Blood, 133 (19). S. 2003 - 2005. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wendtner, Clemens-Martin (2011). Intensive chemotherapy without stem cell transplant for indolent lymphomas. Leuk. Lymphoma, 52 (11). S. 2039 - 2041. LONDON: INFORMA HEALTHCARE. ISSN 1042-8194

Wendtner, Clemens-Martin (2014). Otlertuzumab more than a TRU(E) toddler in CLL? Blood, 123 (9). S. 1282 - 1287. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Wendtner, Clemens-Martin, Byrd, John C., Eichhorst, Barbara, Foa, Robin, Hallek, Michael, Hillmen, Peter, Jager, Ulrich, Jurczak, Wojciech, Kelemen, Peter, Laribi, Kamel, Munir, Talha, Staber, Philipp B., Stilgenbauer, Stephan and Woyach, Jennifer Ann (2016). A phase II study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor (MIRACLE). J. Clin. Oncol., 34 (15). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Wierda, William, Chyla, Brenda, Eichhorst, Barbara, Schetelig, Johannes, Munir, Talha, Hillmen, Peter, Seymour, John F., Roberts, Andrew W., Coutre, Steven, Jurczak, Wojciech, Mulligan, Stephen P., Wendtner, Clemens-Martin, Davids, Matthew, Boettcher, Sebastian, Cerri, Elisa, Zhou, Lang, Popovic, Relja, Poteracki, Mia, Arzt, Jennifer, Kim, Su Young, Verdugo, Maria, Bhathena, Anahita, Stilgenbauer, Stephan and Hallek, Michael (2017). Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) with 17p Deletion: Outcome and Minimal Residual Disease (MRD) from the Full Population of the Pivotal M13-982 Trial. Clin. Lymphoma Myeloma Leuk., 17. S. S303 - 1. DALLAS: CIG MEDIA GROUP, LP. ISSN 2152-2669

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Klaproth, Holger, Tausch, Eugen, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2015). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Blood, 126 (23). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Engelke, Anja, Langerbeins, Petra, Fink, Anna-Maria, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Bottcher, Sebastian, Eichhorst, Barbara and Hallek, Michael (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Phase II-Trial. Blood, 128 (22). WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

von Tresckow, Julia, Cramer, Paula, Bahlo, Jasmin, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Illmer, Thomas, Klaproth, Holger, Estenfelder, Sven, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael (2019). CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia, 33 (5). S. 1161 - 1173. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551

von Tresckow, Julia ORCID: 0000-0001-5873-4603, Cramer, Paula ORCID: 0000-0003-4046-9922, Robrecht, Sandra, Langerbeins, Petra, Fink, Anna-Maria, Al-Sawaf, Othman, Fuerstenau, Moritz, Illmer, Thomas, Klaproth, Holger, Tausch, Eugen, Ritgen, Matthias, Fischer, Kirsten, Wendtner, Clemens-Martin, Kreuzer, Karl-Anton, Stilgenbauer, Stephan, Boettcher, Sebastian, Eichhorst, Barbara F. and Hallek, Michael ORCID: 0000-0002-7425-4455 (2022). Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial. Leukemia, 36 (8). S. 2125 - 2129. LONDON: SPRINGERNATURE. ISSN 1476-5551

This list was generated on Sat Jun 15 09:14:17 2024 CEST.